Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies


AUD 22.77
As of 2020/10/23

1-Day Change
AUD 0.07 (0.31%)
As of 2020/10/23

Morningstar Rating

Key investment risks:
• The Fund may invest in any one or a combination of the following instruments:
– futures, options and swaps and other financial derivative instruments (“FDI”) for investment purposes, up to 10% of the net asset value ("NAV") of the Fund. Given the leverage effect of FDI, such investments may result in substantial loss


(as much as 100% of the NAV of the relevant Fund);
– debt securities rated below investment grade; and
– mortgage and asset-backed securities and/or in index/structured securities. These financial instruments may be rated below investment grade.
• Investing in any one of the above instruments may involve substantial credit/counterparty, market, liquidity, currency, leverage, index, interest and swap risks. If the issuers default, or such securities or their underlying assets, cannot be realised or perform badly, investors’ entire investments may be lost.
• The Fund's investments involve developing markets. Owing to its potentially higher volatility and risk levels, as well as lower political and economic stability than developed markets, asset values could be affected in various levels.
• The Fund’s investments may be more concentrated in terms of industry risk than others that diversify across industries and may therefore be subject to higher industry risk than funds with more diversified holdings.
• The investment decision is yours. If you are in any doubt about the contents of this document, you should seek independent professional financial advice.
• Investors should not only base on this document alone to make investment decisions and should read the Prospectus including the risk factors for further details.




The Fund aims to provide capital growth over the long term.


The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.



  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care


Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.


Discrete Performance (%)
As of 2020/09/30
Quarter End
As of 2020/09/30
Sep-2019 - Sep-2020 Sep-2018 - Sep-2019 Sep-2017 - Sep-2018 Sep-2016 - Sep-2017 Sep-2015 - Sep-2016
25.60% -8.99% 15.10% 12.28% -1.45%
Cumulative Performance (%)
As of 2020/09/30
A2 HAUD (Net)
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
A2 HAUD -0.85% 4.19% 25.88% 6.50% 25.60% 31.57% 45.59% 121.30%
ANNUAL FEES & EXPENSES (As of Fiscal Year End, 2020/06/30)
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2020/06/30)


Top Holdings (As of 2020/09/30)
Merck & Co Inc 3.71
UnitedHealth Group Inc 3.51
Novartis AG (ADR) 3.36
Thermo Fisher Scientific Inc 3.09
Roche Holding AG 3.04
AbbVie Inc 2.99
AstraZeneca PLC 2.98
Abbott Laboratories 2.58
Humana Inc 2.56
Boston Scientific Corp 2.41
Total 30.23
Sector Allocation % OF FUND % OF FUND (As of 2020/09/30)
Health Care 99.59
Cash & Equivalents 0.41
Regional Allocations % OF FUND % OF FUND (As of September 30, 2020)
North America 80.78
Europe 16.84
Japan 1.45
Asia/Pacific Ex Japan 0.52
Cash & Equivalents 0.41